AngioDynamics (ANGO) director receives 11,887-share stock award

Rhea-AI Filing Summary

Licitra Karen A reported acquisition or exercise transactions in this Form 4 filing.

AngioDynamics Inc. director Karen A. Licitra received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units as regular annual compensation for board service. These units immediately vested at grant, increasing her direct holdings to 102,322 shares.

Insider Trade Summary

Net Buyer: 11,887 shares

Net Buy 1 txn

Insider Licitra Karen A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	11,887	$0.00	$0.00

Holdings After Transaction: Common Stock — 102,322 shares (Direct)

Footnotes (1)

1. F1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

Key Figures

Shares granted: 11,887 shares Transaction date: 2026-07-15 Grant price per share: $0.0000 +1 more

4 metrics

Shares granted 11,887 shares Restricted stock units granted as regular annual director compensation

Transaction date 2026-07-15 Date of equity award to director Karen A. Licitra

Grant price per share $0.0000 Reported transaction price per share for the stock award

Holdings after transaction 102,322 shares Karen A. Licitra direct AngioDynamics common stock holdings following the award

Key Terms

restricted stock units, regular annual compensation, immediately vested

3 terms

restricted stock units financial

"represents 11,887 restricted stock units granted as regular annual compensation"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

regular annual compensation financial

"restricted stock units granted as regular annual compensation for service as a director"

immediately vested financial

"The restricted stock units immediately vested at the time of grant"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/22/2026 - 08:06 PM Accepted by SEC EDGAR 07/22/2026 - 08:06 PM Learn about SEC filing dates

FAQ

What insider equity award did AngioDynamics (ANGO) report for director Karen A. Licitra?

AngioDynamics reported that Karen A. Licitra received a grant of 11,887 shares of common stock, representing restricted stock units granted as regular annual compensation for her service as a director, with the award immediately vesting at the time of grant.

How many AngioDynamics (ANGO) shares does Karen A. Licitra hold after the reported Form 4 transaction?

Following the reported award, Karen A. Licitra directly holds 102,322 AngioDynamics shares. This reflects the addition of 11,887 shares received through immediately vested restricted stock units granted as part of her regular annual director compensation package.

On what date was Karen A. Licitra’s AngioDynamics (ANGO) stock award granted?

The stock award to Karen A. Licitra was granted on July 15, 2026. On that date she received 11,887 shares of common stock, issued as restricted stock units that immediately vested as regular annual compensation for her service on the board of directors.

Was cash paid for Karen A. Licitra’s 11,887-share AngioDynamics (ANGO) award?

No cash was paid for this award; the reported transaction price per share is $0.0000. The 11,887 shares represent restricted stock units granted as part of her regular annual director compensation, which vested immediately upon grant rather than being purchased in the market.

What type of instrument was used for Karen A. Licitra’s AngioDynamics (ANGO) equity compensation?

The equity compensation consisted of 11,887 restricted stock units (RSUs) that settle in common stock. These RSUs were granted as regular annual compensation for serving as a director and were structured to immediately vest at the time of grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Licitra Karen A

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		11,887(1)	A	$0	102,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)